Study Protocol for DeCOmPRESS: Defining the Disease Course and Immune Profile of COVID-19 in the Immunosuppressed Patient

The ongoing coronavirus disease 2019 (COVID-19) pandemic is caused by severe acute respiratory syndrome 2 (SARS-CoV-2). Current advisory guidelines for high-risk groups—including people with autoimmune taking immunosuppressive therapies—are to take increased precautions and avoid any unnecessary contacts. The aim of the DeCOmPRESS study define course immune profile COVID-19 in immunosuppressed patients. We will clinically phenotype patients ANCA-associated vasculitis (AAV) who develop using a customized REDCap data collection instrument embedded within Rare Kidney Disease (RKD) Biobank. This dataset be interoperable rheum-COVID, Global Rheumatology Alliance, SPRINT-SARI datasets, facilitating international linkage. Acute convalescent blood samples analysed flow cytometry ELISA immunophenotype cytokine profile. Patients track AAV symptoms through bespoke smartphone app. findings rapidly inform management contract defining natural history immunological manifestations these also determine whether pre-existing immunosuppressant therapy lessens storm associated disease, thereby paradoxically improving rather than worsening clinical outcomes. protocol document details procedures end-to-end completion project complemented an comprehensive Study Manual (accessible at: https://www.tcd.ie/medicine/thkc/decompress/).